The third quarterly report of listed companies has disclosed that many pharmaceutical stocks have performed well, coupled with the marginal improvement of medical insurance policies, the industry believes that with the overall repair of market sentiment, it is expected to usher in performance opportunities, optimistic about medical equipment, traditional Chinese medicine, etc.
in the sub-sectors.
The medical equipment industry will increase significantly in the next two years
The performance of the medical equipment industry this year is relatively strong, and the revenue of enterprises is at the top level in the biomedical industry, mostly due to the increase
in orders.
In terms of net profit, a total of 18 companies achieved a year-on-year increase in net profit, of which 7 companies increased their net profit by more than 60% year-on-year, namely BGI Intelligent Manufacturing, Yiheda, Sinocare Biologics, Kaikai Medical, Huakang Medical, Jinhao Medical and Xiangsheng Medical
.
The analysis believes that the medical equipment industry has good growth and independent and controllable attributes compared to the entire industry, and the industry increment in the next two years is relatively large, and it can be expected that the head companies that carry out high-end upgrade equipment and challenge imports have greater opportunities
.
"The short-term performance of this sector will have a strong outbreak, and in the medium and long term, it will also do something in the direction of import substitution and going abroad, and it is worth paying attention to and investing for a long
time.
"
Deppon Securities pointed out that with the continuous improvement of national health demand, medical equipment will usher in long-term expansion
.
It is expected that the demand for domestic medical equipment will accelerate in the next three years, and the market space will continue to expand
.
The overall market size of the traditional Chinese medicine industry can exceed 1 trillion yuan
The traditional Chinese medicine industry also performed well in the third quarter, with nearly 40% of the companies achieving both revenue and net profit attributable to the parent, among which Baiyunshan, Yunnan Baiyao, Pian Tsaixi, Jeju Pharmaceutical, and China Resources Sanjiu returned to the parent with higher net profits, achieving 884 million yuan, 804 million yuan, 738 million yuan, 577 million yuan and 519 million yuan
respectively.
In the medium and long term, under the background of aging population and consumption upgrading, the Chinese medicine industry will continue to develop
.
At the same time, the Chinese medicine industry is strongly supported
by favorable policies.
The agency pointed out that in recent years, from top-level design to specific measures, the state has introduced a number of policies to encourage the development of
traditional Chinese medicine.
Especially in the past two years, Chinese medicine policies including medical insurance payment, optimization of review and approval rules, encouragement of traditional Chinese medicine innovation and talent development have been intensively introduced, which fully demonstrates China's importance and support
for the inheritance and innovation of traditional Chinese medicine.
The industry expects that the Chinese medicine industry will maintain double-digit growth during the "14th Five-Year Plan" period, and the overall market size can exceed 1 trillion yuan
.
Recently, affected by favorable policies and good performance in the third quarter, the Chinese medicine sector has ushered in a counter-trend upward trend, rising by nearly 20%
since the end of September.
The industry believes that the current valuation of the sector is low, and with the intensive increase of favorable policies and the improvement of corporate operations, the sector will usher in a double repair
of valuation and performance.
The concentration of chain pharmacies is expected to further increase
The total revenue of the six top listed chain pharmacies in the first three quarters reached 63.
923 billion yuan, and the cumulative net profit exceeded 5 billion yuan, of which many chain pharmacies such as Da Shenlin, Laomin and Yifeng Pharmacy increased revenue and profits
in the first three quarters.
The industry believes that industry concentration is expected to further increase
in the future.
The four major businesses of "direct operation + merger and acquisition + franchise + alliance" of chain pharmacies have gone hand in hand, and the number of stores has grown steadily, of which the number of stores of ordinary people has exceeded 10,000
.
In addition, the total number of stores of Yifeng Pharmacy, Da Shenlin and Yixintang is close to 10,000, and it is expected to enter the ranks of
"10,000 stores" in the fourth quarter.
In addition to medical equipment, traditional Chinese medicine, chain pharmacies and other subdivisions, the head enterprises of the innovative drug industry chain and medical services are also optimistic
about the industry.
In general, innovation is the main theme and future development trend of the pharmaceutical industry, whether it is medical devices, traditional Chinese medicine or innovative drugs, enterprises need to seize the innovation trend, continuously increase investment in research and development, and improve competitiveness in order to gain a firm foothold
in the market.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
